189 related articles for article (PubMed ID: 32854402)
21. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
[TBL] [Abstract][Full Text] [Related]
22. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
[TBL] [Abstract][Full Text] [Related]
23. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).
Hu E; Chen N; Bourbeau MP; Harrington PE; Biswas K; Kunz RK; Andrews KL; Chmait S; Zhao X; Davis C; Ma J; Shi J; Lester-Zeiner D; Danao J; Able J; Cueva M; Talreja S; Kornecook T; Chen H; Porter A; Hungate R; Treanor J; Allen JR
J Med Chem; 2014 Aug; 57(15):6632-41. PubMed ID: 25062128
[TBL] [Abstract][Full Text] [Related]
24. Aminoalkyl Derivatives of 8-Alkoxypurine-2,6-diones: Multifunctional 5-HT
Chłoń-Rzepa G; Zagórska A; Żmudzki P; Bucki A; Kołaczkowski M; Partyka A; Wesołowska A; Kazek G; Głuch-Lutwin M; Siwek A; Starowicz G; Pawłowski M
Arch Pharm (Weinheim); 2016 Dec; 349(12):889-903. PubMed ID: 27869315
[TBL] [Abstract][Full Text] [Related]
25. Continuation of structure-activity relationship study of novel benzamide derivatives as potential antipsychotics.
Xu M; Guo S; Yang F; Wang Y; Wu C; Jiang X; Zhao Q; Chen W; Tian G; Zhu F; Xie Y; Hu T; Wang Z; He Y; Shen J
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800306. PubMed ID: 30702760
[TBL] [Abstract][Full Text] [Related]
26. Chemical puzzles in the search for new, flexible derivatives of lurasidone as antipsychotic drugs.
Zaręba P; Drabczyk AK; Jaśkowska J; Satała G
Bioorg Med Chem; 2020 May; 28(10):115459. PubMed ID: 32247749
[TBL] [Abstract][Full Text] [Related]
27. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
28. In the search for a lead structure among series of potent and selective hydantoin 5-HT
Latacz G; Lubelska A; Jastrzębska-Więsek M; Partyka A; Sobiło A; Olejarz A; Kucwaj-Brysz K; Satała G; Bojarski AJ; Wesołowska A; Kieć-Kononowicz K; Handzlik J
Chem Biol Drug Des; 2017 Dec; 90(6):1295-1306. PubMed ID: 28886235
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of binding affinities for 6,7-dimethoxy-4-pyrrolidylquinazolines as phosphodiesterase 10A inhibitors using the linear interaction energy method.
Kjellgren ER; Glue OE; Reinholdt P; Meyer JE; Kongsted J; Poongavanam V
J Mol Graph Model; 2015 Sep; 61():44-52. PubMed ID: 26188794
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.
Li Z; Huang J; Sun H; Zhou S; Guo L; Zhou Y; Zhen X; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):5838-46. PubMed ID: 25308766
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of a series of piperidine-2,6-dione-piperazine (piperidine) derivatives as multireceptor atypical antipsychotics.
Chen Y; Xu X; Liu X; Liu BF; Zhang G
Arch Pharm (Weinheim); 2012 Nov; 345(11):859-69. PubMed ID: 22886598
[TBL] [Abstract][Full Text] [Related]
32. Structure-5-HT receptor affinity relationship in a new group of 7-arylpiperazynylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-amino-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione.
Żmudzki P; Chłoń-Rzepa G; Bojarski AJ; Zygmunt M; Kazek G; Mordyl B; Pawłowski M
Arch Pharm (Weinheim); 2015 Apr; 348(4):229-41. PubMed ID: 25773578
[TBL] [Abstract][Full Text] [Related]
33. The impact of spacer structure on 5-HT7 and 5-HT1A receptor affinity in the group of long-chain arylpiperazine ligands.
Bojarski AJ; Duszyńska B; Kołaczkowski M; Kowalski P; Kowalska T
Bioorg Med Chem Lett; 2004 Dec; 14(23):5863-6. PubMed ID: 15501057
[TBL] [Abstract][Full Text] [Related]
34. The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups.
Tan A; Kizilkaya S; Kelestemur U; Akdemir A; Kara Y
Anticancer Agents Med Chem; 2020; 20(11):1368-1378. PubMed ID: 32275494
[TBL] [Abstract][Full Text] [Related]
35. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition.
Hamaguchi W; Masuda N; Miyamoto S; Shiina Y; Kikuchi S; Mihara T; Moriguchi H; Fushiki H; Murakami Y; Amano Y; Honbou K; Hattori K
Bioorg Med Chem; 2015 Jan; 23(2):297-313. PubMed ID: 25515954
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
38. 5-HT
Ostrowska K; Grzeszczuk D; Głuch-Lutwin M; Gryboś A; Siwek A; Leśniak A; Sacharczuk M; Trzaskowski B
Bioorg Med Chem; 2018 Jan; 26(2):527-535. PubMed ID: 29269256
[TBL] [Abstract][Full Text] [Related]
39. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
[TBL] [Abstract][Full Text] [Related]
40. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
Vardigan JD; Lange HS; Tye SJ; Fox SV; Smith SM; Uslaner JM
Psychopharmacology (Berl); 2016 Jul; 233(13):2441-50. PubMed ID: 27117142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
